272. The incidence of adenocarcinoma of the esophagus is currently increasing and accounts for 50% of esophageal carcinomas in some series
L, Bernstein (Los Angeles)

273. What is the current status of investigations on the role of drugs and dietary changes?
L. Bernstein (Los Angeles)

274. Experimental columnar metaplasia in the canine esophagus has demonstrated columnar cells capable of producing morphological differences in mucin distribution
R.J.S. Thomas (Melbourne)

275. Is there an animal model for CLE and esophageal adenocarcinoma?
T.C. Smyrk (Omaha)

276. Can any conclusion be drawn from increased expression of EGFR (epidermal growth factor receptor) in gastric and esophageal adenocarcinomas?
A. Yasui (Shizuoka)

277. Could the accumulation of free radicals explain the development of tumoral forms of Barrett's esophagus by their effect on nucleic acids?
M. Mathonnet, A. Gainant, P. Cubertafond (Limoges)

278. Does the presence of LIMA (large intestine mucin antigen) OF SIMA (small intestine mucin antigen) and acid mucins suggest that adenocarcinomas with or without CLE arise from a common cell type?
R.J.S. Thomas (Melbourne)

279. How can the incidence of carcinoma in Barrett's esophagus be satisfactorily assessed? - What are the shortcomings of the different incidence studies?
SJ. Spechler (Boston)

280. What are the radiologic appearances of Barrett's carcinoma?
M.S. Levine (Philadelphia)

281. What is the endoscopic aspect of early Barrett's cancer?
G.N.J. Tytgat (Netherlands)

282. Is an initial multifocal or diffuse appearance characteristic of adenocarcinoma in CLE?
JA. Roth (Houston)

283. How useful is cytology in the diagnosis of carcinoma in CLE?
K.R. Geisinger (Winston-Salem)

284. What are the minimal criteria for the biopsy diagnosis of well-differentiated adenocarcinomas?
H.D. Appelman (Ann Arbor)

285. Does adenocarcinoma accompanying high-grade dysplasia have a particular tendency to metastasis?
T.C. Smyrk (Omaha)

286. Does the finding of aneuploidy as opposed to diploidy on flow cytometry indicate a different prognosis for adenocarcinoma of the esophagus?
M. Robaszkiewicz (Brest)

287. What is the histologic differential diagnosis for Barrett's carcinoma?
H.D. Appelman (Ann Arbor)

288. Do all adenocarcinomas of the esophagus arise in Barrett's mucosa?
J.H. Peters, G.W.B. Clark, T.R. DeMeester (Los Angeles)

289. Does the identical specific chromosomal rearrangements recently identified in adenocarcinomas of gastric and esophageal origin suggest that these tumors are biologically related? What is the clinical value of oncogene amplification and protein overexpression?
Y. Nabeya, N.K. Altorki, A.P. Albino (New York)

290. Does squamous cell carcinoma complicate Barrett's mucosa?
S.R. Hamilton (Baltimore)

291. What are the characteristic differences between adenocarcinoma arising in CLE and squamous cell carcinoma of the esophagus?
A.H. Holscher, E. Bollschweiler, J.R. Siewert (Munich)

292. What are the indications of laser therapy for esophageal cancer?
R. Lambert (Lyons)

293. What can be expected from the use of Protoporphyrins?
R. Lambert (Lyons)

294. How should the intraoperative staging to switch from curative to palliative procedure be conducted?
M. Endo (Tokyo)

295. What is gained from mediastinal nodal clearance during surgical resection of adenocarcinoma arising in CLE?
T.R. DeMeester, J.A. Hagen, J.H. Peters, G.W.B. Clark (Los Angeles)

296. What are the advantages of using the colon rather than the stomach for esophageal reconstruction?
T.R. DeMeester, S. Johnson (Los Angeles)

297. Operability and resectability rates are higher in adenocarcinomas arising in CLE than in other types of esophageal cancer, but is late survival higher?
R. Bardini, M. Asolati, L. Bonavina, A. Ruol, A. Peracchia (Padua)